OptiNose (NASDAQ:OPTN) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of OptiNose (NASDAQ:OPTN) from a buy rating to a hold rating in a report published on Thursday morning, Zacks.com reports.

According to Zacks, “OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company’s lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. “

A number of other research firms have also weighed in on OPTN. Cantor Fitzgerald reaffirmed a buy rating and issued a $27.00 price objective on shares of Spero Therapeutics in a research note on Thursday, May 9th. Piper Jaffray Companies set a $29.00 price objective on shares of OptiNose and gave the stock a buy rating in a research note on Tuesday, April 23rd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. OptiNose currently has a consensus rating of Buy and an average price target of $23.30.



NASDAQ:OPTN opened at $8.00 on Thursday. OptiNose has a 1-year low of $5.66 and a 1-year high of $28.04. The business has a 50-day simple moving average of $7.22. The company has a quick ratio of 6.74, a current ratio of 6.95 and a debt-to-equity ratio of 0.79.

OptiNose (NASDAQ:OPTN) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.70) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.01. OptiNose had a negative net margin of 983.22% and a negative return on equity of 81.04%. The company had revenue of $4.48 million during the quarter, compared to analyst estimates of $4.35 million. Analysts predict that OptiNose will post -2.97 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in OPTN. BlackRock Inc. lifted its stake in OptiNose by 69.0% in the fourth quarter. BlackRock Inc. now owns 1,820,167 shares of the company’s stock worth $11,285,000 after acquiring an additional 743,369 shares during the period. Rice Hall James & Associates LLC lifted its stake in OptiNose by 32.9% in the first quarter. Rice Hall James & Associates LLC now owns 1,414,682 shares of the company’s stock worth $14,571,000 after acquiring an additional 349,820 shares during the period. JPMorgan Chase & Co. lifted its stake in OptiNose by 8.1% in the first quarter. JPMorgan Chase & Co. now owns 2,503,969 shares of the company’s stock worth $25,791,000 after acquiring an additional 187,174 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new stake in shares of OptiNose during the fourth quarter valued at about $1,108,000. Finally, Two Sigma Investments LP purchased a new stake in shares of OptiNose during the fourth quarter valued at about $646,000. 63.68% of the stock is owned by institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Featured Article: Why are trading ranges significant?

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.